Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma

被引:25
|
作者
Lin, Ching-Jung [1 ]
Hsu, Teh-Fu [1 ,2 ,3 ]
Chang, Yen-Hou [1 ,3 ]
Huang, Ben-Shian [1 ,3 ,4 ]
Jiang, Ling-Yu [1 ,3 ]
Wang, Peng-Hui [1 ,3 ,4 ]
Chen, Yi-Jen [1 ,3 ,4 ,5 ]
机构
[1] Taipei Vet Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Emergency Med, Taipei, Taiwan
[3] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[4] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan
[5] Cheng Hsin Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan
来源
关键词
Adenomyosis; Adenomyoma; Conservative uterine-sparing surgery; Gonadotropin releasing hormone agonist; Levonorgestrel-releasing intrauterine system; MEDICAL-TREATMENT; AND/OR ADENOMYOMA; PELVIC PAIN; THERAPY; TRIAL; WOMEN;
D O I
10.1016/j.tjog.2017.12.036
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing the recurrence of postoperative adenomyosis-related symptoms. Materials and methods: From January 2005 through December 2014, a retrospective study including 133 patients with symptomatic adenomyosis undergoing conservative uterine-sparing surgery followed by gonadotropin-releasing hormone agonist treatment was conducted. We excluded the 18 patients who did not meet the inclusion criteria. The patients of intervention group (n = 54) received a levonorgestrelreleasing intrauterine system (LNG-IUS), which was inserted after surgery. The patients without LNG-IUS insertion were enrolled in the control group (n = 61). The primary outcome was improvement of adenomyosis-related dysmenorrhea, which was evaluated by the visual analog scale (VAS) and by hemoglobin (Hgb) and CA-125 levels. Results: Over a 12-month follow-up, the intervention group exhibited a greater reduction in dysmenorrhea as assessed with a VAS score (mean +/- SD: 6.5 +/- 2.5 vs 4.1 +/- 3.6, p = 0.001) and a greater elevation in the Hgb level (2.1 +/- 1.9 vs 1.0 +/- 1.7, p = 0.008) than the control group. At the end of the 24-month follow-up period, the intervention group also exhibited a greater reduction in dysmenorrhea as assessed with a VAS score (mean +/- SD 6.1 +/- 2.7 vs 3.7 +/- 3.7, p = 0.002) and a greater elevation in the Hgb level (1.9 +/- 2.1 vs 0.7 +/- 1.8, p = 0.022) than the control group. The CA-125 level was significantly lower in the intervention group during the postoperative follow up (12th month follow-up, intervention vs control, 24.5 +/- 28.8 vs 50.1 +/- 44.0, p = 0.005; 24th month follow-up, 28.6 +/- 26.2 vs 75.4 +/- 68.5, p = 0.002). Conclusion: The maintenance therapy of LNG-IUS is effective and well accepted for long-term therapy after conservative surgery for patients with adenomyosis. (C) 2018 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 50 条
  • [21] Selection and performance of the levonorgestrel-releasing intrauterine system
    Lahteenmaki, P
    Bardin, CW
    Elomaa, K
    Haukkamaa, M
    Kivijarvi, A
    Kuukankorpi, A
    Venhola, M
    Tuominen, J
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1997, 76 : 69 - 74
  • [22] The levonorgestrel-releasing intrauterine system and endometriosis staging
    Oliveira Gomes, Mariana Kefalas
    Ferriani, Rui Alberto
    Rosa E Silva, Julio Cesar
    Vieira, Carolina Sales
    Candido dos Reis, Francisco Jose
    [J]. FERTILITY AND STERILITY, 2007, 87 (05) : 1231 - 1234
  • [23] Levonorgestrel-releasing Intrauterine System - The discontinuing story
    Ewies, Ayman A. A.
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (10) : 668 - 673
  • [24] Uterine perforation by the levonorgestrel-releasing intrauterine device: case report
    Lajtman, Erik
    Uharcek, Peter
    Mlyncek, Milos
    [J]. GYNECOLOGICAL SURGERY, 2009, 6 (03) : 277 - 279
  • [25] Uterine Perforation by Levonorgestrel-Releasing Intrauterine Device: A Case Report
    Roman, Jose D.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [26] Levonorgestrel-releasing intrauterine devices
    Cohen, I
    [J]. LANCET, 2001, 357 (9258): : 801 - 801
  • [27] Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment
    Hai, Ning
    Hou, Qingxiang
    Guo, Ruijun
    [J]. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2021, 38 (01) : 65 - 69
  • [28] Scope of levonorgestrel-releasing intrauterine system (MIRENA) for symptomatic relief and uterine size reduction in adenomyosis and associated endometriosis.
    Chakravarty, M.
    Ganesh, A. L.
    Chakravarty, B. N.
    [J]. FERTILITY AND STERILITY, 2007, 88 : S215 - S215
  • [29] Treatment of heavy menstrual bleeding associated with uterine leiomyoma with the levonorgestrel-releasing intrauterine system
    Shawki, O.
    El-Sherbiny, Waleed
    Saber, Waleed
    Askalany, Ahmed
    El-Daly, Ashraf
    [J]. GYNECOLOGICAL SURGERY, 2009, 6 (04) : 331 - 337
  • [30] Breast levonorgestrel concentrations in women using a levonorgestrel-releasing intrauterine system
    Depypere, Herman T.
    Stanczyk, Frank Z.
    Croubels, Siska
    Blondeel, Phillip N.
    Roche, Nathalie A.
    Depypere, Bernard P.
    Vanhaecke, Lynn
    [J]. CONTRACEPTION, 2019, 100 (04) : 299 - 301